Halper Sadeh Investigates EKSO Merger and Other Transactions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Source: Globenewswire
- Legal Investigation Launched: Halper Sadeh LLC is investigating EKSO Bionics Holdings, Inc.'s merger with Applied Digital Cloud for potential violations of federal securities laws and fiduciary duties to shareholders, which could impact shareholder rights.
- Acquisition Transaction Review: Amicus Therapeutics, Inc. is being sold to BioMarin Pharmaceutical Inc. for $14.50 per share, and Halper Sadeh LLC may seek to negotiate a higher consideration for shareholders to ensure their legal rights are upheld.
- Cash Acquisition Scrutiny: Clearwater Analytics Holdings, Inc. is being sold for $24.55 per share in cash to Permira and Warburg Pincus, with Halper Sadeh LLC potentially requesting additional disclosures to protect shareholder interests.
- Shareholder Rights Advocacy: Janus Henderson Group plc is being sold to Trian Fund Management and General Catalyst for $49.00 per share, and Halper Sadeh LLC will represent shareholders in seeking further relief and benefits to ensure transparency and fairness in the transaction.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on CWAN
Wall Street analysts forecast CWAN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CWAN is 27.83 USD with a low forecast of 24.55 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
5 Buy
5 Hold
0 Sell
Moderate Buy
Current: 24.130
Low
24.55
Averages
27.83
High
36.00
Current: 24.130
Low
24.55
Averages
27.83
High
36.00
About CWAN
Clearwater Analytics Holdings, Inc. is a provider of comprehensive cloud-native platforms for institutional investors across global public and private markets. The Company’s single-instance, multi-tenant architecture delivers real-time data and artificial intelligence (AI)-driven insights throughout the investment lifecycle. The platform eliminates information silos by integrating portfolio management, trading, investment accounting, reconciliation, regulatory reporting, performance, compliance, and risk analytics in one unified system. The Company serves insurers, asset managers, hedge funds, banks, corporations, and governments. The Company is also a provider of enterprise risk analytics and developer infrastructure. Its capabilities in complex portfolio management across both public and private markets include structured products, private credit, and derivatives.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street Analysts Adjust Ratings on Key Stocks
- Emerson Electric Downgrade: Oppenheimer analyst Christopher Glynn downgraded Emerson Electric Co (NYSE:EMR) from Outperform to Perform, reflecting market caution regarding its future growth, with shares closing at $149.13 on Monday.
- Skywater Technology Rating Change: Needham analyst N. Quinn Bolton downgraded Skywater Technology Inc (NASDAQ:SKYT) from Buy to Hold, indicating concerns about its short-term performance, as shares closed at $32.35 on Monday.
- Bitdeer Technologies Downgrade and Price Target Cut: Keefe, Bruyette & Woods analyst Stephen Glagola downgraded Bitdeer Technologies Group (NASDAQ:BTDR) from Outperform to Market Perform and cut the price target from $26.5 to $14, reflecting pessimism about its future profitability, with shares closing at $13.90 on Monday.
- Procter & Gamble Rating Adjustment: TD Cowen analyst Robert Moskow downgraded Procter & Gamble Co (NYSE:PG) from Buy to Hold, although raising the price target to $156, shares still closed at $149.49 on Monday, indicating market divergence regarding its growth potential.
Continue Reading
Wall Street Analysts Adjust Ratings
- Acumen Price Target Raised: BTIG raised Acumen Pharmaceuticals' price target from $4 to $7, with analyst Thomas Shrader maintaining a Buy rating, indicating confidence in the company's growth potential despite a closing price of $2.08 on Monday.
- Exelixis Target Price Increase: HC Wainwright & Co. raised the price target for Exelixis from $49 to $52, with analyst Robert Burns maintaining a Buy rating, reflecting optimism about its market performance, closing at $43.61 on Monday.
- Baker Hughes Price Target Upgraded: BMO Capital increased Baker Hughes' price target from $55 to $65, with analyst Phillip Jungwirth maintaining an Outperform rating, suggesting a positive outlook on its future performance, closing at $56.29 on Monday.
- Brown & Brown Price Target Cut: B of A Securities lowered the price target for Brown & Brown from $94 to $90, with analyst Joshua Shanker maintaining a Neutral rating, indicating a cautious stance on the company's short-term performance, closing at $79.62 on Monday.
Continue Reading